AbbVie Unveils Positive Phase III TEMPO-2 Trial Findings for Tavapadon as Parkinson's Disease Monotherapy
AbbVie announced favorable topline results from its pivotal Phase III TEMPO-2 trial, which assessed the investigational drug tavapadon as a flexible-dose monotherapy for early-stage Parkinson's disease. Tavapadon is the first and only D1/D5 partial agonist being studied as a once-daily treatment for Parkinson's disease.
The TEMPO-2 trial investigated the efficacy, safety, and tolerability of a flexible-dose regimen (5 mg to 15 mg once daily) of tavapadon as a monotherapy in adults with early Parkinson's disease. The trial achieved its primary endpoint, showi...